Ask AI
ProCE Banner Activity

Considerations in Selecting Therapy for Previously Treated CLL

Slideset Download
Download this slideset from a live symposium at ASH 2022 for expert perspectives on best practices in treating patients with relapsed/refractory CLL.

Released: December 09, 2022

Review Activity

Share

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

This CE activity is supported through an educational grant from

AstraZeneca

BeiGene

Lilly

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Faculty Disclosure

Primary Author

Jennifer Woyach, MD

Director, Division of Hematology
Bertha Bournocle MD and Andrew Pereny Chair of Medicine
Co-Director, Leukemia and Hematologic Malignancies Research Program
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Jennifer Woyach, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo, NewWave, Pharmacyclics; researcher: Schrödinger.